摘要
胆管癌是一种主要起源于胆管上皮细胞,具有高度异质性和侵袭性的恶性肿瘤,未经治疗的胆管癌患者中位生存时间为12~24个月,手术切除和新辅助化疗有效性和持久性均有限。下一代测序发现免疫系统失调在胆管癌的发病机制中起重要作用,为针对侵袭性胆管癌自然进程的治疗研究提供了新可能,如免疫检查点抑制剂、过继细胞治疗和肿瘤疫苗等。笔者立足胆管癌免疫治疗的现状,综合阐述目前胆管癌免疫治疗策略的疗效和困境,展望胆管癌未来治疗前景。
Cholangiocarcinoma(CCA)is a category of highly heterogeneous and aggressive malignancy mainly originating from bile duct epithelial cells.The median survival time of untreated CCA patients is approximately 12‒24 months,and the effectiveness and durability of surgical resection and neoadjuvant chemotherapy are limited.Results of the next-generation sequencing show that dysregulation of the immune system plays an important role in the pathogenesis of CCA.It has opened up new possibilities for the study of therapies targeting the natural course of aggressive CCA,such as immune checkpoint inhibitors,adoptive cell therapy,and tumor vaccines.Based on the current status of immunotherapy for CCA,the authors review the efficacy and dilemmas of current CCA immunotherapy strategies and look forward to the future treatment prospects of CCA.
作者
左石
陈乾
邹卫龙
Zuo Shi;Chen Qian;Zou Weilong(Department of Hepatobiliary Surgery,Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China)
出处
《中华消化外科杂志》
CAS
CSCD
北大核心
2022年第7期873-879,共7页
Chinese Journal of Digestive Surgery
基金
贵州省优秀青年科技人才专项基金(20195628)
贵州省卫生健康委员会科学技术基金项目(gzwjkj2020⁃1⁃101)
贵阳市科技局大健康项目(20199⁃1⁃2)。
关键词
胆道肿瘤
免疫治疗
免疫检查点抑制剂
肿瘤微环境
过继细胞治疗
肿瘤疫苗
Bile tract neoplasms
Immunotherapy
Immune checkpoint inhibitors
Tumor microenvironment
Adoptive cell therapy
Tumor vaccine
